|Last Price$11.81||Day Change (%)0.17%|
|Open Price$11.81||Day Change ($)0.02|
|Day Range11.81–11.81||52-Week Range10.33–12.30|
As of Thu 12/18/2014 09:31 AM EST | USD
Fitch Affirms Progressive's Ratings Following ARX Controlling Interest Acquisition
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
Fitch Affirms Montpelier's Ratings; Outlook Revised to Negative
We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.
An examination of 10 CEFs with the highest duration risk.
Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting